摘要
目的探讨伊立替康联合5-氟尿嘧啶(5-FU)和左亚叶酸钙治疗晚期结肠癌的疗效及对血清糖类抗原125(CA125)、糖类抗原199(CA199)、T细胞亚群水平的影响。方法回顾性分析医院2015年6月至2017年6月收治的晚期结肠癌患者84例,按治疗方法的不同分为对照组和研究组,各42例。对照组患者予以5-FU联合左亚叶酸钙治疗,研究组患者在此基础上加用伊立替康治疗。结果研究组总有效率为42. 86%,明显高于对照组的21. 43%(P <0. 05);与治疗前比较,两组患者治疗后的血清CA199及CA125水平均明显降低(P <0. 05),且研究组较对照组变化显著(P <0. 05);研究组患者治疗后的CD_3^+及CD_4^+水平均明显升高(P <0. 05),CD_8^+水平均明显降低(P <0. 05);两组不良反应发生率无明显差异(P> 0. 05)。结论伊立替康联合5-FU和左亚叶酸钙可用于晚期结肠癌的治疗,其机制与降低血清肿瘤标志物水平和增强免疫力有关。
Objective To investigate the clinical effect of irinotecan combined with 5-fluorouracil(5-FU)and calcium levofolinate in the treatment of advanced colon cancer and its effect on serum carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)and T cell subsets.Methods The clinical data of 84 patients with advanced colon cancer in our hospital from June 2015 to June 2017 were analyzed retrospectively.The patients were divided into the control group and the study group according to different treatment methods,42 cases in each group.The patients in the control group were treated with 5-FU combined with calcium levofolinate,on this basis,the patients in the study group were treated with irinotecan.Results The total effective rate of the study group was 42.86%,which was significantly higher than 21.43%of the control group(P<0.05).Compared with before treatment,the levels of serum CA199 and CA125 in the two groups were significantly lower after treatment(P<0.05),and the changes in the study group were more significant than those in the control group(P<0.05).After treatment,the levels of CD3^+and CD4^+were significantly increased,while the levels of CD8^+were significantly decreased in the study group(P<0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion Irinotecan combined with 5-FU and calcium levofolinate can be used in the treatment of advanced colon cancer.Its mechanism is related to the reduction of sercm tumor markers and the enhancement of immunity.
作者
石磊
付晓伶
张珏
SHI Lei;FU Xiaoling;ZHANG Jue(Shuguang Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai,China 200135)
出处
《中国药业》
CAS
2019年第6期47-49,共3页
China Pharmaceuticals
关键词
伊立替康
晚期
结肠癌
糖类抗原125
糖类抗原199
T细胞亚群
临床疗效
作用机制
irinotecan
advanced
colon cancer
carbohydrate antigen 125
carbohydrate antigen 199
T cell subsets
clinical effect
mechanism of action
